BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27695345)

  • 1. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.
    Doan HQ; Silapunt S; Migden MR
    Onco Targets Ther; 2016; 9():5671-5678. PubMed ID: 27695345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.
    Jain S; Song R; Xie J
    Onco Targets Ther; 2017; 10():1645-1653. PubMed ID: 28352196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
    Brancaccio G; Pea F; Moscarella E; Argenziano G
    Front Oncol; 2020; 10():582866. PubMed ID: 33194718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.
    Fecher LA; Sharfman WH
    Biologics; 2015; 9():129-40. PubMed ID: 26604681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sonidegib phosphate: new approval for basal cell carcinoma.
    Tibes R
    Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
    Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
    Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response.
    Gambini D; Passoni E; Nazzaro G; Beltramini G; Tomasello G; Ghidini M; Kuhn E; Garrone O
    Front Med (Lausanne); 2022; 9():893063. PubMed ID: 35775005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness.
    Silapunt S; Chen L; Migden MR
    Ther Adv Med Oncol; 2016 Sep; 8(5):375-82. PubMed ID: 27583029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma.
    Cucchi D; Occhione MA; Gulino A; De Smaele E
    J Exp Pharmacol; 2012; 4():173-85. PubMed ID: 27186130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma.
    Aditya S; Rattan A
    Indian Dermatol Online J; 2013 Oct; 4(4):365-8. PubMed ID: 24350028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
    Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
    Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonidegib for the treatment of advanced basal cell carcinoma.
    Ramelyte E; Amann VC; Dummer R
    Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.